

YOU HAVE THE POWER TO **DISRUPT AND DESTROY BIOFILM** TO ADVANCE HEALING


78% CHANCE

NON-HEALING WOUNDS NEED MORE THAN SILVER[™]



2 TECHNOLOGIES, 1 SOLUTION

Biofilm is one of the major causes of delayed wound healing^{1,2}



Biofilm is present in at least 78% of chronic wounds³

Biofilm can be defined as microbial cells adherent to a living or non-living surface, which are embedded within a self-produced matrix of extra-cellular polymeric substances (EPS). Biofilm provides tolerance to antimicrobial agents and can result in persistent inflammation and infection.4,5



RECOVERY MODE

Biofilm is difficult to remove completely as it is attached to the wound bed. Biofilm can reform in as little as 24h, even following aggressive debridement.⁶

To prevent biofilm reformation, effective long-lasting antimicrobial protection is needed.⁶



ATTACK MODE

Biofilm can spread and form new colonies by constantly releasing micro-organisms from the mature biofilm structure.7

This can increase the risk of crossinfection both within the wound and in the surrounding environment.8



DEFENCE MODE

EPS shields micro-organisms from antibiotics, antiseptics and the host's immune response.⁵


This biofilm-specific defence and the inability to breach the EPS matrix contributes to a chronic inflammatory state in the wound environment.4


Biofilm cannot always be seen with the naked eye and sometimes even wounds that do not show clear signs of infection may contain biofilm.


Macroscopic view












MORE THAN SILVER[™] technology designed to **disrupt and destroy** biofilm

Specifically developed to win the battle against biofilm, MORE THAN SILVER[™] technology contains three components; ionic silver together with a surfactant and metal chelating agent, which work together to deliver superior*⁹ anti-biofilm performance.



The result of years of research

Developing MORE THAN SILVER[™] technology involved researching a wide range of biofilm-disrupting agents and surfactants in combination with antimicrobials.⁹

250,000 POTENTIAL COMBINATIONS WERE IDENTIFIED

60,000 WERE TESTED

* When compared to AQUACEL® Ag+ Extra dressing and other silver-only competitor dressings: ACTICOAT™ 7 and SILVERCEL™ Non-Adherent dressings † Benzethonium chloride

[‡] Ethylenediaminetetraacetic acid disodium salt

Winning the battle to advance healing

AQUACEL® Ag+ dressings advance healing in stalled, deteriorating, chronic wounds

A real life evaluation of clinical cases¹⁷

111 patients across 60 centres in UK and Ireland – wound duration ranging from 1 week to 30 years


54% of wounds showed clinical signs of biofilm presence at baseline

78% of wounds

healed or progressed to healing during an average evaluation period of 3.9 weeks

99% of clinicians

would recommend the use of AQUACEL[®] Ag+ Extra[™] dressings



Case studies: Advancing healing in chronic wounds

Example 1 - the wound:

Diabetic foot ulcer (6+ months) with the following clinical signs: odour, exudate, slough, suspected biofilm.

Results

AQUACEL[®] Ag+ dressings: peri-wound skin improved, wound bed improved, healed in 5 weeks.

Example 2 - the wound:

Stalled foot ulcer (3 months): no improvement following antibiotic therapy and standard silver dressing.

Results

AQUACEL[®] Ag+ dressings: change from sloughy to granulation tissue. Ulcer healed in less than 7 weeks.





10 days

15 days



45 days

37 days



Dressing Size	Pack size	Product Code	
AQUACEL® Ag+ Extra™ Dressings			
5cm x 5cm	10	413566	
10cm x 10cm	10	413567	
15cm x 15cm	5	413568	
20cm x 30cm	5	413569	
4cm x 10cm	10	413581	
4cm x 20cm	10	413598	
4cm x 30cm	10	413599	

Dressing Size	Pack size	Product Code	
AQUACEL* Ag+ Ribbon Dressings			
1cm x 45cm	5	413570	
2cm x 45cm	5	413571	

To learn more about AQUACEL® Ag+ or to arrange a visit from your ConvaTec representative, please call

convatec

ConvaTec (Australia) Pty Limited. Customer Support Freecall: 1800 339 412 www.convatec.com.au ConvaTec (New Zealand) Limited. Phone: 0800 441 763 www.convatec.co.nz

Hurlow, J., Couch, K., Laforet, K., Bolton, L., Metcalf, D. et al. (2015). Clinical Biofilms: A Challenging Frontier in Wound Care. Advances in Wound Care, 4(5), 295-301.
Metaling: a review of the evidence. Burns Trauma 2013; 1: 5-12.
Malone M et al. 2017. The prevalence of biofilm in chronic wounds: a systematic review and meta-analysis of published data. JWC; 20-25.
Gurjala AN et al. Development of a novel, highly quantitative in vivo model for the study of biofilm-impaired cutaneous wound healing. Wound Rep Reg (2011) 19 400-410.
Hall-Stoodley L I et al. Towards diagnostic guidelines for biofilm-sensoriated infections. FEMS Immunol Med Microbiol. 2012; 65:127–145.
Kourd Care. 2010; 19:320-328.
Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms: A Common Cause of PersistentInfections. 1999; 284 Science.
Saye DE. Recurring and antimicrobial-resistant infections. Considering the potential role of biofilms in clinical practice Ostomy Wound Management 2007 53:4 (46-62).
Sudward Care, 2010; 19:320-328.
Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilm sci Acommon Cause of PersistentInfections. 1999; 284 Science.
Saye DE. Recurring and antimicrobial-resistant infections.
Sound Medicine 14 (2016) 6–11.
Said J, Walker M, Parsons D, Stapleton P, Beezer AE, Gaisford S. An in vitro test of the efficacy of an anti-biofilm wound dressing. Int J Pharmaceutics. 2014; 474: 177–181. DOI: 10.1016/j.
Borlam Z, Zooda A, B. Chelator Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in Bio Im. Appl. Environ. Microbiol. 72. 2064 2069.
Chen X, Stewart PS, 2000. Biofilm revealence of a novel, antimicrobial ressing on invico. Pseudomonas aeruginosa wound biofilm anturinicrobial dressing on invico. Pseudomonas aeruginosa wound biofilm and the ssing on invico. Pseudomonas aeruginosa wound dressing on bacterial ultrast